Mylan launches generic ovarian cancer drug

mylan

Mylan Inc announced on Monday that it has launched Carboplatin Injection, which is the generic version of Bristol-Myers Squibb’s Paraplatin® Injection. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents.  

Read the source article at ca.finance.yahoo.com

About the Author

Leave a Reply